On October 19, 2026 PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, reported six poster presentations at the 18th International Congress on Myeloproliferative Neoplasms, taking place October 29-30 in Brooklyn, New York.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentations span essential thrombocythemia (ET) and polycythemia vera (PV), with a particular focus on real-world treatment patterns and outcomes. Three retrospective analyses use U.S. claims and community oncology data to examine how patients with ET and PV are being treated in clinical practice, including patterns of BESREMi (ropeginterferon alfa-2b-njft) utilization and treatment persistence in PV, characteristics of patients initiating first-line BESREMi or other cytoreductive therapies for PV, and treatment patterns and unmet needs among patients with ET.

"Across ET and PV, these data point to the same conclusion: current treatment approaches leave substantial unmet need, and patients would benefit from therapies that do more than only control blood counts," said Albert Qin, M.D., Ph.D., Chief Medical Officer at PharmaEssentia. "With BESREMi now approved for adults with ET or PV in the U.S., we have an opportunity to reshape how myeloproliferative neoplasms are treated. We will continue to build evidence beyond the clinical trial setting to help physicians bring BESREMi to the patients who stand to benefit most."

A systematic review and meta-analysis examine disease-specific long-term outcomes following first-line hydroxyurea in ET and PV. Two further presentations evaluate BESREMi’s effect on JAK2 V617F allele burden. The first is an exploratory analysis of two Phase 3 studies comparing rapid versus slow BESREMi titration in Japanese patients with PV. The second is a multicenter retrospective analysis of real-world BESREMi use in Chinese patients with MPNs. BESREMi is designed to address the underlying disease by targeting disease-driving cells in the bone marrow, and the reductions in JAK2 V617F allele burden seen in the Japanese and Chinese analyses provide a molecular measure of that activity.

Key results presented:

ET treatment patterns: Only one-third of an estimated 159,000 U.S. patients with ET had received treatment. Hydroxyurea accounted for 94% of first-line therapy, and patients who switched cycled largely between hydroxyurea and anagrelide, the comparator over which BESREMi demonstrated superior durable response rates in the Phase 3 SURPASS ET study.
Hydroxyurea outcomes: Thrombosis was the most frequent disease-related event in both PV and ET, with risk persisting throughout follow-up, and toxicity or intolerance accounted for about one-third of reported discontinuations.
BESREMi persistence and treatment sequencing in PV: Among patients starting first-line therapy, 55.0% on BESREMi remained on treatment at 24 months. Among all BESREMi-treated patients, those younger than 60 received it earlier in their treatment sequence and had higher 24-month persistence than older patients (60.5% vs. 32.0%).
First-line BESREMi in community practice: Patients starting first-line BESREMi had a longer median time from PV diagnosis to treatment than those starting other cytoreductive therapies, mostly hydroxyurea (7.7 vs. 0.6 months). This is consistent with initial management with phlebotomy and aspirin. They were also younger (median 63 vs. 73 years) and more often low risk (32% vs. 8%).
Rapid titration in Japan: The 250-350-500 mcg BESREMi regimen, approved for PV in Japan and the U.S. dosing schedule for ET, was associated with numerically greater JAK2 V617F allele burden reduction at Week 24 (12.66% vs. 7.50%) and similar complete hematologic response as compared to those treated with slower titration.
Real-world BESREMi in China: In 87 Chinese patients with MPNs (mainly ET and PV) treated with the 250-350-500 mcg titration, complete hematologic response rose from 62% at 3 months to 78% at 12 months. JAK2 V617F allele burden fell by an average of 1.89% per month of treatment. All adverse events were grade 1–2, most commonly abnormal liver function tests.
Poster Presentations

All six posters will be presented during the Congress poster session on October 29 at 5:45 p.m. ET.

Title: Long-Term Outcomes Following First-Line Hydroxyurea in Polycythemia Vera and Essential Thrombocythemia: A Systematic Review and Meta-Analysis
Poster Number: 118
Presenter: Megan Metzger, M.D., Perlmutter Cancer Center, NYU Langone Health

Title: Real-World Treatment Patterns and Unmet Needs in Essential Thrombocythemia From US Claims Data
Poster Number: 161
Presenter: Pankit Vachhani, M.D., University of Alabama at Birmingham

Title: Age-Based Differences in Ropeginterferon Alfa-2b Utilization and Treatment Persistence in Polycythemia Vera: Real-World Evidence from US Claims Data
Poster Number: 162
Presenter: Shaoyu Chang, M.D., M.P.H., PharmaEssentia USA

Title: Real-World Characteristics and Treatment Patterns Among Patients Initiating First-Line Ropeginterferon Alfa-2b or Other Cytoreductive Therapies for Polycythemia Vera
Poster Number: 140
Presenter: Mark Faber, D.O., Banner MD Anderson Cancer Center

Title: Impact of Rapid versus Slow Titration of Ropeginterferon alfa‑2b on JAK2 V617F Allele Burden in Japanese Patients with Polycythemia Vera
Poster Number: 138
Presenter: Rieko Sagara, PharmaEssentia Japan

Title: Real-World Experience of Ropeginterferon Alfa-2b in Chinese Patients with Myeloproliferative Neoplasms: A Multicenter Retrospective Analysis of 87 Cases
Poster Number: 112
Presenter: Sujiang Zhang, M.D., Ph.D., Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

(Press release, PharmaEssentia, OCT 19, 2026, View Source [SID1234673588])